Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.40 |
| ▸ | YES1 | P07947 | 4/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349182 | 0.86 | PIK3CA (0.44) | MAPK1FLT3PIK3CA | |
| SCHEMBL629296 | 0.81 | MAPK1 (0.46) | MAPK1AURKBYES1NTRK1EGFR | |
| SCHEMBL630415 | 0.80 | EGFR (0.53) | MAPK1AURKBYES1NTRK1FLT3 | |
| SCHEMBL629467 | 0.80 | EGFR (0.61) | MAPK1AURKBYES1NTRK1FLT3 | |
| SCHEMBL629518 | 0.80 | LCK (0.46) | EGFR | |
| SCHEMBL629420 | 0.79 | EGFR (0.52) | MAPK1AURKBYES1NTRK1FLT3 | |
| SCHEMBL629704 | 0.78 | ABL1 (0.45) | MAPK1AURKBYES1NTRK1EGFR | |
| SCHEMBL630518 | 0.78 | AURKB (0.61) | MAPK1AURKBYES1NTRK1FLT3 | |
| SCHEMBL629037 | 0.78 | MAPK1 (0.61) | MAPK1AURKBYES1HIPK1ABL1 | |
| SCHEMBL629381 | 0.78 | RAB9A (0.52) | MAPK1AURKBYES1NTRK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102378758-A | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH | 2012-03-14 | — | — | CN | claimed |
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | claimed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | claimed |
| EP-2241557-A1 | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | Æterna Zentaris GmbH (DE) | 2010-10-20 | — | — | EP | claimed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| CN-102378758-A | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH | 2012-03-14 | — | — | CN | disclosed |
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2241557-A1 | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | Æterna Zentaris GmbH (DE) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241557-A1 | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | Æterna Zentaris GmbH (DE) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | NQO2, G6PD, GLS2 | MAPK1 2140/4885AURKB 2506/4885YES1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.